Skip to content

Photodynamic diagnostic method using aminolevulinic acid against thoracic malignant tumors

Development of photodynamic diagnostic method using aminolevulinic acid (5-ALA) against thoracic malignant tumors - PDTMT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs011180023
Enrollment
300
Registered
2019-03-19
Start date
2013-07-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chest malignancy Chest malignancy

Interventions

In the morning of surgery, 20 mg / kg of aminolevulinic acid hydrochloride (5-ALA-HCl) was orally administered 4 hours before introduction of anesthesia, and a high sensitivity color CCD camera (Trimo

Sponsors

Kitada Masahiro
Lead Sponsor
Ohsaki Yoshinobu
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients with chest malignancy (lung cancer, metastatic lung tumor, malignant breast tumor, thoracic lymph node metastasis from breast cancer) . 2.Surgical samples with diagnosis of chest malignancy on image or pathological diagnosis. 3.Cases requiring diagnosis by thoracoscopic biopsy including lymph nodes. 4.After receiving sufficient explanation about this exam, after understanding the sufficient understanding, cases where document agreement was acquired with the free will of the patient himself / herself.

Exclusion criteria

Exclusion criteria: 1. Cases of pregnancy or lactation. 2. Patients with porphyria. 3. Drugs that are known to cause photosensitivity: tetracycline antibiotics, sulfonamide type preparations, new quinolone type antibacterial agents, hypericin (Hypericum perforatum extract), etc. St. John's Wort patients who are receiving food containing. 4. Cases with chronic hepatitis, chronic renalfailure. 5. Cases in which the result of treatment of malignant tumor does not change by this procedure.

Design outcomes

Primary

MeasureTime frame
Improvement rate of diagnosis of chest malignancy when photodynamic diagnosis is used in combination.

Secondary

MeasureTime frame
Improvement rate of diagnosis of lymph node metastasis in case of combined use of photodynamic diagnosis, and presence or absence of adverse event.

Contacts

Public ContactMasaru Abe

Asahikawa Medical University

rs-kk.g@asahikawa-med.ac.jp+81-166-68-2261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026